Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Psychiatry ; 21(4): 251-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16530390

ABSTRACT

PURPOSE: Sexual dysfunction in patients with schizophrenia can reduce quality of life and treatment compliance. This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year. SUBJECTS AND METHODS: Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188). RESULTS: Based on patient perception, the odds of experiencing sexual dysfunction during 1 year of therapy was significantly lower for patients treated with olanzapine and quetiapine when compared to patients who received risperidone or haloperidol (all P< or =0.001). Females on olanzapine (14%) or quetiapine (8%) experienced a lower rate of menstrual irregularities, compared to females on risperidone (23%) or haloperidol (29%). Significant discordance was evident between patient reports and psychiatrist perception of sexual dysfunction, with psychiatrists underestimating sexual dysfunction (P< or =0.001). CONCLUSION: These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia.


Subject(s)
Antipsychotic Agents/adverse effects , Health Surveys , Outpatients/psychology , Outpatients/statistics & numerical data , Schizophrenia/drug therapy , Sexual Dysfunction, Physiological/epidemiology , Adult , Analysis of Variance , Antipsychotic Agents/therapeutic use , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Dibenzothiazepines/adverse effects , Dibenzothiazepines/therapeutic use , Female , Haloperidol/adverse effects , Haloperidol/therapeutic use , Humans , Male , Odds Ratio , Olanzapine , Prevalence , Prospective Studies , Quetiapine Fumarate , Risperidone/adverse effects , Risperidone/therapeutic use , Time , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...